Advertisement

Lung Cancer Medications

Here's a list of the approved drugs to treat lung cancer. Click on any of the medications for more info on indications, dosing and side effects.


Quick Filter

*generic version available

E experimental

DRUG Chemotherapy
GENERIC NAME Multiple
DRUG INDICATION

Cytotoxic chemotherapy, the oldest and most commonly used type of cancer treatment, halts cell division and kills rapidly growing cells. For a full list of chemotherapy drugs, click here.

DRUG Zepzelca
GENERIC NAME lurbinectedin
DRUG INDICATION

Zepzelca is an alkylating drug approved for the treatment of metastatic small-cell lung cancer that has progressed during or after platinum-based chemotherapy.

DRUG Imfinzi
GENERIC NAME durvalumab
DRUG INDICATION

Imfinzi is a checkpoint inhiibtor approved for advanced or metastatic bladder (urothelial) cancer, inoperable non-small-cell lung cancer and extensive-stage small cell lung cancer.

DRUG Keytruda
GENERIC NAME pembrolizumab
DRUG INDICATION

Keytruda is a PD-1 checkpoint inhibitor approved for inoperable or metastatic melanoma, adjuvant treatment of melanoma after surgery, non-small-cell lung cancer, bladder (urothelial) cancer, head and neck cancer, esophageal cancer, liver cancer, kidney cancer, relapsed or refractory classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, Merkel cell carcinoma and cutaneous squamous cell carcinoma. It is also approved for all metastatic solid tumors with high microsatellite instability or mismatch repair deficiency mutations (MSI-H/dMMR) or high tumor mutation burden. 

DRUG Opdivo
GENERIC NAME nivolumab
DRUG INDICATION

Opdivo is a checkpoint inhibitor approved for inoperable or metastatic melanoma, metastatic or recurrent non-small-cell lung cancer, metastatic small-cell lung cancer, advanced kidney cancer, relapsed or refractory classical Hodgkin lymphoma, recurrent or metastatic head and neck cancer, advanced or metastatic bladder (urothelial) cancer, liver cancer, recurrent or metastatic esophageal cancer and colorectal cancer with high microsatellite instability or mismatch repair deficiency genetic mutations. 

DRUG Tecentriq
GENERIC NAME atezolizumab
DRUG INDICATION

Tecentriq is a checkpoint inhibitor approved for the treatment of advanced or metastatic bladder (urothelial) cancer, metastatic non-small-cell lung cancer, extensive-stage small-cell lung cancer, triple-negative breast cancer, metastatic liver cancer and inoperable or metastatic melanoma.

DRUG Yervoy
GENERIC NAME ipilimumab
DRUG INDICATION

Yervoy is a checkpoint inhibitor approved for advanced or metastatic melanoma, and in combination with Opdivo for kidney cancer (renal cell carcinoma), colorectal cancer with high microsatellite instability or mismatch repair deficiency genetic mutations (MSI-high/dMMR), advanced liver cancer and metastatic or recurrent non-small-cell lung cancer.

DRUG Alecensa
GENERIC NAME alectinib
DRUG INDICATION

Alecensa is an anaplastic lymphoma kinase (ALK) inhibitor approved for the treatment of ALK-positive non-small-cell lung cancer (NSCLC).

DRUG Alunbrig
GENERIC NAME brigatinib
DRUG INDICATION

Alunbrig is an anaplastic lymphoma kinase inhibitor approved for the treatment of ALK-positive metastatic non-small-cell lung cancer.

DRUG Avastin
GENERIC NAME bevacizumab
DRUG INDICATION

Avastin is a VEGF inhibitor approved for the treatment of metastatic colorectal cancer, non-squamous non-small cell lung cancer, metastatic kidney cancer (renal cell carcinoma), recurrent or metastatic cervical cancer, recurrent glioblastoma brain cancer, liver cancer, and ovarian, fallopian tube or primary peritoneal cancer. Mvasi and Zirabev are biosimilar medications.

DRUG Cyramza
GENERIC NAME ramucirumab
DRUG INDICATION

Cyramza is a VEGFR2 inhibitor approved for treatment of cancer of the stomach or gastroesophageal junction (where the stomach meets the esophagus), metastatic non-small-cell lung cancer, metastatic colorectal cancer and inoperable or metastatic liver cancer.

DRUG Erbitux
GENERIC NAME cetuximab
DRUG INDICATION

Erbitux is an EGFR inhibitor approved for treatment of advanced or metastatic head and neck cancer and EGFR-positive metastatic colorectal cancer without KRAS mutations.

DRUG Gavreto
GENERIC NAME pralsetinib
DRUG INDICATION

Gavreto is a kinase inhibitor approved for the treatment of metastatic non-small-cell lung cancer with RET gene fusions.

DRUG Gilotrif
GENERIC NAME afatinib
DRUG INDICATION

Gilotrif is a kinase inhibitor approved for people with metastatic non-small-cell lung cancer (NSCLC) with EGFR mutations who are being treated for the first time or who have experienced disease progression on chemotherapy.

DRUG Iressa
GENERIC NAME gefitinib
DRUG INDICATION

Iressa is a tyrosine kinase inhibitor approved for people with metastatic non-small-cell lung cancer (NSCLC) with certain EGFR mutations who are being treated for the first time.

DRUG Lorbrena
GENERIC NAME lorlatinib
DRUG INDICATION

Lorbrena is an anaplastic lymphoma kinase inhibitor approved for people with previously treated ALK-positive non-small-cell lung cancer.

DRUG Mekinist
GENERIC NAME trametinib
DRUG INDICATION

Mekinist is a kinase inhibitor approved to treat certain cancers with BRAF V600 mutations. It can be used alone to treat people with inoperable or metastatic melanoma. It is approved in combination with the companion drug Tafinlar for treatment of inoperable or metastatic melanoma and for prevention of melanoma recurrence after surgery. The combination is also approved for metastatic non-small-cell lung cancer (NSCLC) and advanced thyroid cancer.

DRUG Portrazza
GENERIC NAME necitumumab
DRUG INDICATION

Portrazza is an EGFR inhibitor approved for the first-line treatment of people with metastatic squamous non-small-cell lung cancer (NSCLC) in combination with chemotherapy.

DRUG Retevmo
GENERIC NAME selpercatinib
DRUG INDICATION

Retevmo is a kinase inhibitor approved for the treatment of metastatic non-small-cell lung cancer and advanced or metastatic thyroid cancer with RET gene fusions or mutations.

DRUG Rozlytrek
GENERIC NAME entrectinib
DRUG INDICATION

Rozlytrek is approved for the treatment of solid tumors anywhere in the body that have NTRK gene fusions and for ROS1-positive non-small-cell lung cancer.

DRUG Tabrecta
GENERIC NAME capmatinib
DRUG INDICATION

Tabrecta is a kinase inhibitor approved for the treatment of metastatic non-small-cell lung cancer with a specific genetic mutation.

DRUG Tafinlar
GENERIC NAME dabrafenib
DRUG INDICATION

Tafinlar is a kinase inhibitor approved to treat certain cancers with BRAF V600 mutations. It can be used alone to treat people with inoperable or metastatic melanoma. It is approved in combination with the companion drug Mekinist for treatment of inoperable or metastatic melanoma and for prevention of melanoma recurrence after surgery. The combination is also approved for metastatic non-small-cell lung cancer (NSCLC) and advanced thyroid cancer.

DRUG Tagrisso
GENERIC NAME osimertinib
DRUG INDICATION

Tagrisso is a kinase inhibitor approved for people with metastatic non-small-cell lung cancer (NSCLC) with certain EGFR mutations who are being treated for the first time or who have experienced disease progression on a different EGFR inhibitor.

DRUG Tarceva
GENERIC NAME erlotinib
DRUG INDICATION

Tarceva is an EGFR inhibitor approved for the treatment of metastatic non-small-cell lung cancer (NSCLC) with EGFR mutations, and as first-line therapy for locally advanced, inoperable or metastatic pancreatic cancer, in combination with gemcitabine chemotherapy.

DRUG Vitrakvi
GENERIC NAME larotrectinib
DRUG INDICATION

Vitrakvi is a TRK inhibitor that works against cancers anywhere in the body with NTRK gene fusions.

DRUG Vizimpro
GENERIC NAME dacomitinib
DRUG INDICATION

Vizimpro is a kinase inhibitor approved for people with metastatic non-small-cell lung cancer (NSCLC) with certain EGFR mutations who are being treated for the first time.

DRUG Xalkori
GENERIC NAME crizotinib
DRUG INDICATION

Xalkori is a kinase inhibitor approved for the treatment of metastatic non-small-cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK) or ROS1 positive.

DRUG Zykadia
GENERIC NAME ceritinib
DRUG INDICATION

Zykadia is a kinase inhibitor approved for the treatment of ALK-positive metastatic non-small-cell lung cancer (NSCLC).


Advertisement